Cognitive & Memory Enhancer Drugs Market - Global Forecast 2026-2032

The Cognitive & Memory Enhancer Drugs Market is projected to reach USD 7.84 Billion in 2026. It is expected to continue growing at a CAGR of 10.95%, reaching USD 14.77 Billion by 2032.

Cognitive & memory enhancer drugs span prescription therapies for dementia and Alzheimer’s disease, ADHD and narcolepsy-related attention deficits, and emerging nootropic therapeutics evaluated for measurable cognitive benefit. Demand is grounded in a clear public-health need: the World Health Organization reports more than 55 million people live with dementia worldwide, with nearly 10 million new cases each year.

Market momentum is being shaped by population aging, earlier diagnosis, biomarker-led treatment selection, and the shift from symptomatic dementia pharmacotherapy toward disease-modifying Alzheimer’s disease treatment. Industry participants are also balancing innovation with safety, controlled-substance compliance, pharmacovigilance, and ethical concerns around off-label cognitive enhancement in healthy individuals.

Transformative Shifts in the Cognitive Enhancement Landscape

The cognitive enhancement landscape is moving from broad symptomatic management toward precision neurology. Cholinesterase inhibitors and memantine remain established options for Alzheimer’s-related symptoms, while FDA approvals of anti-amyloid monoclonal antibodies in 2023 and 2024 signaled a new phase for early Alzheimer’s disease treatment.

These advances are transforming care models because disease-modifying therapies require amyloid confirmation, specialist evaluation, infusion capacity, and monitoring for amyloid-related imaging abnormalities. At the same time, stimulant and wakefulness-promoting drugs remain highly regulated, making pharmacovigilance, patient selection, and evidence-based prescribing central to sustainable category development.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is compounding change across cognitive enhancer drug discovery, clinical development, and patient management. AI-enabled target identification, molecular screening, imaging analytics, and digital cognitive assessment can help reduce trial inefficiency and support earlier detection of Alzheimer’s disease, mild cognitive impairment, ADHD, and other neurological conditions.

The cumulative impact is strongest where AI is paired with validated biomarkers, real-world evidence, and human clinical oversight. For industry leaders, the opportunity is not only faster R&D but also safer prescribing, improved adherence programs, and better pharmacovigilance; however, data privacy, algorithmic bias, explainability, and regulatory validation remain essential safeguards.

Key Regional Insights: Global Demand and Access Patterns

Asia-Pacific is a high-priority region as Japan, China, South Korea, and Australia face rapid population aging and rising dementia diagnosis, while India and Southeast Asian markets expand access to neurology care and affordable generics. North America remains a leading hub for clinical trials, FDA-regulated innovation, specialty pharmacy infrastructure, and uptake of new Alzheimer’s disease treatment pathways, supported by established diagnostic, imaging, and infusion networks.

Europe is shaped by rigorous health technology assessment, cost-effectiveness review, pharmacovigilance systems, and national reimbursement decisions, creating disciplined but influential adoption patterns for cognitive enhancer drugs and memory enhancer drugs. Latin America presents growing demand in Brazil and Mexico, though specialist availability, affordability, and reimbursement variability remain constraints. The Middle East, especially Gulf health systems, is investing in advanced hospitals, neurology services, and diagnostics, while Africa’s opportunity is tied to dementia awareness, basic neurological care, trained workforce availability, and access to essential medicines.

Key Group Insights: Policy, Trade, and Clinical Adoption

ASEAN markets are building demand through expanding middle-class healthcare access, hospital investment, and growing awareness of age-related cognitive decline, but uneven reimbursement and specialist capacity affect uptake. The GCC is positioned for premium neurology services, diagnostic modernization, and specialty therapeutics adoption, supported by national health transformation programs and investments in advanced care infrastructure.

The European Union influences global standards through medicines regulation, pharmacovigilance, data protection, and reimbursement scrutiny. BRICS countries combine large patient populations with strong generic-drug capacity and expanding clinical research networks, making affordability and local evidence generation important adoption factors. G7 markets remain central to premium innovation, payer evidence requirements, and early adoption, while NATO members’ focus on health security and supply-chain resilience supports reliable access to critical neurological medicines.

Key Country Insights: Market Priorities Across Major Economies

The United States leads in FDA-approved disease-modifying Alzheimer’s therapies, neuroscience innovation, and large-scale specialty care networks, while Canada emphasizes public reimbursement evaluation, clinical appropriateness, and equitable access. Mexico and Brazil show rising dementia and ADHD treatment demand, supported by urban hospital systems but constrained by affordability, fragmented access, and specialist distribution.

In Europe, the United Kingdom, Germany, France, Italy, and Spain are shaped by national health systems, HTA expectations, reimbursement rules, and neurologist-led prescribing, while Russia’s environment is influenced by local registration, procurement dynamics, and domestic supply priorities. China is scaling dementia care capacity, hospital-based diagnostics, and domestic innovation; India is driven by affordable generics and expanding diagnostics; Japan and South Korea are advanced aging societies with strong neurology infrastructure and high awareness of cognitive decline; and Australia combines evidence-based reimbursement with high clinical standards and structured specialist care.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize biomarker-ready clinical strategies, including amyloid or tau confirmation where relevant, MRI monitoring pathways, and clear protocols for managing therapy-associated risks. Organizations should also generate payer-grade evidence that demonstrates cognitive, functional, caregiver, and health-economic value beyond short-term clinical endpoints.

Commercial success will depend on responsible market access, physician education, controlled-substance compliance, and ethical positioning around nonmedical cognitive enhancement. Leaders should invest in AI governance, real-world safety surveillance, inclusive trial recruitment, regional partnerships, and patient support programs that improve adherence while reducing disparities in dementia and cognitive disorder care.

Research Methodology

This executive summary is developed through a structured secondary-research approach using publicly available, authoritative sources such as WHO health data, regulatory communications from agencies including the FDA and EMA, clinical trial registries, peer-reviewed literature, approved prescribing information, and health-system policy documentation. Insights are triangulated across epidemiology, regulation, reimbursement, technology, and clinical activity.

The methodology emphasizes verified evidence over speculative claims. Interpretation focuses on observable drivers, including aging demographics, approved drug classes, clinical development trends, AI-enabled R&D, pharmacovigilance requirements, and regional access conditions. Findings are reviewed for consistency, medical accuracy, and relevance to cognitive enhancer drugs, memory enhancer drugs, nootropic therapeutics, ADHD medications, and Alzheimer’s disease treatment.

Conclusion: Responsible Growth in Cognitive Therapeutics

The cognitive & memory enhancer drugs landscape is entering a more evidence-intensive phase as aging populations, Alzheimer’s disease innovation, ADHD treatment demand, and AI-enabled drug development converge. Momentum will be strongest where therapies demonstrate measurable clinical value, manageable safety profiles, and alignment with payer and regulatory expectations.

The next competitive advantage will come from responsible innovation: validated biomarkers, inclusive trials, ethical commercialization, robust pharmacovigilance, and scalable access models. Organizations that integrate scientific rigor with regional healthcare realities will be best positioned to shape the future of cognitive enhancement and dementia pharmacotherapy.

Additional Product Information:

Purchase of this report includes 1 year online access with quarterly updates.
This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

1. Preface

1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations

3. Executive Summary

3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap

4. Market Overview

4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Cognitive & Memory Enhancer Drugs Market, by Mechanism Of Action

7.1. Introduction
7.2. Cholinesterase Inhibitors
7.2.1. Donepezil
7.2.2. Galantamine
7.2.3. Rivastigmine
7.3. NMDA Antagonists
7.4. Psychostimulants
7.4.1. Amphetamines
7.4.2. Methylphenidate
7.5. Racetams
7.5.1. Aniracetam
7.5.2. Piracetam

8. Cognitive & Memory Enhancer Drugs Market, by Dosage Form

8.1. Introduction
8.2. Capsules
8.3. Injectable
8.4. Oral Powder
8.5. Tablets

9. Cognitive & Memory Enhancer Drugs Market, by Application

9.1. Introduction
9.2. Alzheimer's Disease
9.3. Attention Deficit Hyperactivity Disorder
9.4. General Cognitive Enhancement
9.5. Parkinson's Disease

10. Cognitive & Memory Enhancer Drugs Market, by End User

10.1. Introduction
10.2. Clinics
10.3. Hospitals

11. Cognitive & Memory Enhancer Drugs Market, by Distribution Channel

11.1. Introduction
11.2. Hospital Pharmacies
11.3. Online Pharmacies
11.4. Retail Pharmacies

12. Cognitive & Memory Enhancer Drugs Market, by Region

12.1. Asia-Pacific
12.2. North America
12.3. Latin America
12.4. Europe
12.5. Middle East
12.6. Africa

13. Cognitive & Memory Enhancer Drugs Market, by Group

13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO

14. Cognitive & Memory Enhancer Drugs Market, by Country

14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea

15. Competitive Landscape

15.1. Market Share Analysis, 2025
15.2. FPNV Positioning Matrix, 2025
15.3. Market Concentration Analysis, 2025
15.3.1. Concentration Ratio (CR)
15.3.2. Herfindahl Hirschman Index (HHI)
15.4. Recent Developments & Impact Analysis, 2025
15.5. Product Portfolio Analysis, 2025
15.6. Benchmarking Analysis, 2025

16. Company Profiles

16.1. AbbVie Inc
16.2. Amgen Inc.
16.3. AstraZeneca plc
16.4. Aurobindo Pharma Limited
16.5. Bayer AG
16.6. Biogen Inc
16.7. Cipla Limited
16.8. Dr. Reddy’s Laboratories Limited
16.9. Eisai Co., Ltd
16.10. Eli Lilly and Company
16.11. GlaxoSmithKline plc
16.12. Johnson & Johnson
16.13. Lundbeck A/S
16.14. Lupin Limited
16.15. Merck & Co., Inc.
16.16. Novartis AG
16.17. Otsuka Pharmaceutical Co., Ltd.
16.18. Pfizer Inc
16.19. Roche Holding AG
16.20. Sanofi S.A.
16.21. Sumitomo Pharma Co., Ltd.
16.22. Sun Pharmaceutical Industries Limited
16.23. Takeda Pharmaceutical Company Limited
16.24. Torrent Pharmaceuticals Limited
16.25. UCB S.A.
16.26. Viatris Inc.
16.27. Zydus Lifesciences Limited

List of Figures

FIGURE 1. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2032 (%)
FIGURE 7. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2032 (%)
FIGURE 9. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
FIGURE 11. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 13. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 15. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 19. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 21. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 23. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

List of Tables

TABLE 1. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL CHOLINESTERASE INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL CHOLINESTERASE INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL CHOLINESTERASE INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL DONEPEZIL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL DONEPEZIL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL DONEPEZIL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL GALANTAMINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL GALANTAMINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL GALANTAMINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL RIVASTIGMINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL RIVASTIGMINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL RIVASTIGMINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL NMDA ANTAGONISTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL NMDA ANTAGONISTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL NMDA ANTAGONISTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL PSYCHOSTIMULANTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL PSYCHOSTIMULANTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL PSYCHOSTIMULANTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL AMPHETAMINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL AMPHETAMINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL AMPHETAMINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL METHYLPHENIDATE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL METHYLPHENIDATE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL METHYLPHENIDATE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL RACETAMS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL RACETAMS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL RACETAMS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL ANIRACETAM MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL ANIRACETAM MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL ANIRACETAM MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL PIRACETAM MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL PIRACETAM MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL PIRACETAM MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL CAPSULES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL CAPSULES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL CAPSULES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL ORAL POWDER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL ORAL POWDER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL ORAL POWDER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL TABLETS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL TABLETS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL TABLETS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL ALZHEIMER'S DISEASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL ALZHEIMER'S DISEASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL ALZHEIMER'S DISEASE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL GENERAL COGNITIVE ENHANCEMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL GENERAL COGNITIVE ENHANCEMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL GENERAL COGNITIVE ENHANCEMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL PARKINSON'S DISEASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL PARKINSON'S DISEASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 81. ASIA-PACIFIC COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 82. ASIA-PACIFIC COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 83. ASIA-PACIFIC COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 84. ASIA-PACIFIC COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2017-2032 (USD MILLION)
TABLE 85. ASIA-PACIFIC COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2017-2032 (USD MILLION)
TABLE 86. ASIA-PACIFIC COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 87. ASIA-PACIFIC COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 88. ASIA-PACIFIC COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 89. ASIA-PACIFIC COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 90. NORTH AMERICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 91. NORTH AMERICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 92. NORTH AMERICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 93. NORTH AMERICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2017-2032 (USD MILLION)
TABLE 94. NORTH AMERICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2017-2032 (USD MILLION)
TABLE 95. NORTH AMERICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 96. NORTH AMERICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 97. NORTH AMERICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 98. NORTH AMERICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 99. LATIN AMERICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 100. LATIN AMERICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 101. LATIN AMERICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 102. LATIN AMERICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2017-2032 (USD MILLION)
TABLE 103. LATIN AMERICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2017-2032 (USD MILLION)
TABLE 104. LATIN AMERICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 105. LATIN AMERICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 106. LATIN AMERICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 107. LATIN AMERICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 108. EUROPE COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 109. EUROPE COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 110. EUROPE COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 111. EUROPE COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2017-2032 (USD MILLION)
TABLE 112. EUROPE COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2017-2032 (USD MILLION)
TABLE 113. EUROPE COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 114. EUROPE COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 115. EUROPE COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 116. EUROPE COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 117. MIDDLE EAST COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 118. MIDDLE EAST COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 119. MIDDLE EAST COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 120. MIDDLE EAST COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2017-2032 (USD MILLION)
TABLE 121. MIDDLE EAST COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2017-2032 (USD MILLION)
TABLE 122. MIDDLE EAST COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 123. MIDDLE EAST COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 124. MIDDLE EAST COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 125. MIDDLE EAST COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 126. AFRICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 127. AFRICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 128. AFRICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 129. AFRICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2017-2032 (USD MILLION)
TABLE 130. AFRICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2017-2032 (USD MILLION)
TABLE 131. AFRICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 132. AFRICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 133. AFRICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 134. AFRICA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 135. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 136. ASEAN COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 137. ASEAN COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 138. ASEAN COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 139. ASEAN COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2017-2032 (USD MILLION)
TABLE 140. ASEAN COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2017-2032 (USD MILLION)
TABLE 141. ASEAN COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 142. ASEAN COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 143. ASEAN COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 144. ASEAN COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 145. GCC COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 146. GCC COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 147. GCC COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 148. GCC COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2017-2032 (USD MILLION)
TABLE 149. GCC COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2017-2032 (USD MILLION)
TABLE 150. GCC COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 151. GCC COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 152. GCC COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 153. GCC COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 154. EUROPEAN UNION COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 155. EUROPEAN UNION COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 156. EUROPEAN UNION COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 157. EUROPEAN UNION COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2017-2032 (USD MILLION)
TABLE 158. EUROPEAN UNION COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2017-2032 (USD MILLION)
TABLE 159. EUROPEAN UNION COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 160. EUROPEAN UNION COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 161. EUROPEAN UNION COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 162. EUROPEAN UNION COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 163. BRICS COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 164. BRICS COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 165. BRICS COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 166. BRICS COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2017-2032 (USD MILLION)
TABLE 167. BRICS COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2017-2032 (USD MILLION)
TABLE 168. BRICS COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 169. BRICS COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 170. BRICS COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 171. BRICS COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 172. G7 COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 173. G7 COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 174. G7 COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 175. G7 COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2017-2032 (USD MILLION)
TABLE 176. G7 COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2017-2032 (USD MILLION)
TABLE 177. G7 COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 178. G7 COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 179. G7 COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 180. G7 COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 181. NATO COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 182. NATO COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 183. NATO COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 184. NATO COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2017-2032 (USD MILLION)
TABLE 185. NATO COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2017-2032 (USD MILLION)
TABLE 186. NATO COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 187. NATO COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 188. NATO COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 189. NATO COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 190. GLOBAL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 191. UNITED STATES COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 192. UNITED STATES COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 193. UNITED STATES COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 194. UNITED STATES COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2017-2032 (USD MILLION)
TABLE 195. UNITED STATES COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2017-2032 (USD MILLION)
TABLE 196. UNITED STATES COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 197. UNITED STATES COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 198. UNITED STATES COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 199. UNITED STATES COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 200. CANADA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 201. CANADA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 202. CANADA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 203. CANADA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2017-2032 (USD MILLION)
TABLE 204. CANADA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2017-2032 (USD MILLION)
TABLE 205. CANADA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 206. CANADA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 207. CANADA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 208. CANADA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 209. MEXICO COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 210. MEXICO COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 211. MEXICO COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 212. MEXICO COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2017-2032 (USD MILLION)
TABLE 213. MEXICO COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2017-2032 (USD MILLION)
TABLE 214. MEXICO COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 215. MEXICO COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 216. MEXICO COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 217. MEXICO COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 218. BRAZIL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 219. BRAZIL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 220. BRAZIL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 221. BRAZIL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2017-2032 (USD MILLION)
TABLE 222. BRAZIL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2017-2032 (USD MILLION)
TABLE 223. BRAZIL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 224. BRAZIL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 225. BRAZIL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 226. BRAZIL COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 227. UNITED KINGDOM COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 228. UNITED KINGDOM COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 229. UNITED KINGDOM COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 230. UNITED KINGDOM COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2017-2032 (USD MILLION)
TABLE 231. UNITED KINGDOM COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2017-2032 (USD MILLION)
TABLE 232. UNITED KINGDOM COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 233. UNITED KINGDOM COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 234. UNITED KINGDOM COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 235. UNITED KINGDOM COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 236. GERMANY COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 237. GERMANY COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 238. GERMANY COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 239. GERMANY COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2017-2032 (USD MILLION)
TABLE 240. GERMANY COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2017-2032 (USD MILLION)
TABLE 241. GERMANY COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 242. GERMANY COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 243. GERMANY COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 244. GERMANY COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 245. FRANCE COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 246. FRANCE COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 247. FRANCE COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 248. FRANCE COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2017-2032 (USD MILLION)
TABLE 249. FRANCE COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2017-2032 (USD MILLION)
TABLE 250. FRANCE COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 251. FRANCE COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 252. FRANCE COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 253. FRANCE COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 254. RUSSIA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 255. RUSSIA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 256. RUSSIA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 257. RUSSIA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2017-2032 (USD MILLION)
TABLE 258. RUSSIA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2017-2032 (USD MILLION)
TABLE 259. RUSSIA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 260. RUSSIA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 261. RUSSIA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 262. RUSSIA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 263. ITALY COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 264. ITALY COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 265. ITALY COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 266. ITALY COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2017-2032 (USD MILLION)
TABLE 267. ITALY COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2017-2032 (USD MILLION)
TABLE 268. ITALY COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 269. ITALY COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 270. ITALY COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 271. ITALY COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 272. SPAIN COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 273. SPAIN COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 274. SPAIN COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 275. SPAIN COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2017-2032 (USD MILLION)
TABLE 276. SPAIN COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2017-2032 (USD MILLION)
TABLE 277. SPAIN COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 278. SPAIN COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 279. SPAIN COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 280. SPAIN COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 281. CHINA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 282. CHINA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 283. CHINA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 284. CHINA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2017-2032 (USD MILLION)
TABLE 285. CHINA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2017-2032 (USD MILLION)
TABLE 286. CHINA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 287. CHINA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 288. CHINA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 289. CHINA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 290. INDIA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 291. INDIA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 292. INDIA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 293. INDIA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2017-2032 (USD MILLION)
TABLE 294. INDIA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2017-2032 (USD MILLION)
TABLE 295. INDIA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 296. INDIA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 297. INDIA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 298. INDIA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 299. JAPAN COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 300. JAPAN COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 301. JAPAN COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 302. JAPAN COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2017-2032 (USD MILLION)
TABLE 303. JAPAN COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2017-2032 (USD MILLION)
TABLE 304. JAPAN COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 305. JAPAN COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 306. JAPAN COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 307. JAPAN COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 308. AUSTRALIA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 309. AUSTRALIA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 310. AUSTRALIA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 311. AUSTRALIA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2017-2032 (USD MILLION)
TABLE 312. AUSTRALIA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2017-2032 (USD MILLION)
TABLE 313. AUSTRALIA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 314. AUSTRALIA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 315. AUSTRALIA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 316. AUSTRALIA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 317. SOUTH KOREA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 318. SOUTH KOREA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 319. SOUTH KOREA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 320. SOUTH KOREA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY PSYCHOSTIMULANTS, 2017-2032 (USD MILLION)
TABLE 321. SOUTH KOREA COGNITIVE & MEMORY ENHANCER DRUGS MARKET SIZE, BY RACETAMS, 2017-2032 (USD MILLION)
TABLE 322. SOUTH KOREA COGNITIV

Companies Mentioned

AbbVie Inc
Amgen Inc.
AstraZeneca plc
Aurobindo Pharma Limited
Bayer AG
Biogen Inc
Cipla Limited
Dr. Reddy’s Laboratories Limited
Eisai Co., Ltd
Eli Lilly and Company
GlaxoSmithKline plc
Johnson & Johnson
Lundbeck A/S
Lupin Limited
Merck & Co., Inc.
Novartis AG
Otsuka Pharmaceutical Co., Ltd.
Pfizer Inc
Roche Holding AG
Sanofi S.A.
Sumitomo Pharma Co., Ltd.
Sun Pharmaceutical Industries Limited
Takeda Pharmaceutical Company Limited
Torrent Pharmaceuticals Limited
UCB S.A.
Viatris Inc.
Zydus Lifesciences Limited

Table Information

Report Attribute	Details
No. of Pages	196
Published	August 2026
Forecast Period	2026 - 2032
Estimated Market Value ( USD ) in 2026	$ 7.84 Billion
Forecasted Market Value ( USD ) by 2032	$ 14.77 Billion
Compound Annual Growth Rate	10.9%
Regions Covered	Global
No. of Companies Mentioned	27

License	Format	Properties	Price
1 - 5 USER LICENSE PDF, Excel and Online Access		This is a 1-5 user license, allowing up to five users have access to the product.	€3184EUR$3,545USD£2,720GBP €3538EUR$3,939USD£3,022GBP
ENTERPRISE LICENSE PDF, Excel and Online Access		This is an enterprise license, allowing all employees within your organization access to the product.	€4817EUR$5,363USD£4,115GBP €5352EUR$5,959USD£4,572GBP

Transformative Shifts in the Cognitive Enhancement Landscape

Cumulative Impact of Artificial Intelligence

Key Regional Insights: Global Demand and Access Patterns

Key Group Insights: Policy, Trade, and Clinical Adoption

Key Country Insights: Market Priorities Across Major Economies

Actionable Recommendations for Industry Leaders

Research Methodology

Conclusion: Responsible Growth in Cognitive Therapeutics

Table of Contents

Companies Mentioned

Table Information

Related Topics

Related Reports

Cognitive and Memory Enhancer Drugs Market Report by Product, Application, and Region 2026-2034

Memory Enhancement Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

Dementia Associated with Alzheimer's Disease Market - Global Strategic Business Report

Frontotemporal Dementia Market - Global Strategic Business Report

Vascular Dementia Market Report 2026